Gruenenthal purchased rights to Protect's IP covering two advanced products for an undisclosed drug combination for pain for $1.6 million up front

Protect Pharmaceuticals Corp.

U.S. / Small-Cap Biopharma (<$1 billion)

Seller

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Gruenenthal Group

Germany / Private Biopharma

Buyer

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced